Evaluation of 2-year experience with EGFR mutation analysis of small diagnostic samples

Diagnostic Molecular Pathology

Volumn 22, Issue 2, 2013, Pages 70-75

  Hlinkova, Katarina ^a   Babal, Pavel ^b   Berzinec, Peter ^c   Majer, Ivan ^b   Mikle Barathova, Zdenka ^d   Piackova, Barbora ^a   Ilencikova, Denisa ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^c SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^d Histopathology and Cytology Laboratory   (Slovakia)

Author keywords

DNA quality; EGFR mutation analysis; NSCLC subtypes; Tumor cellularity

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HETEROZYGOTE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR CELL;

BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; FORMALDEHYDE; GENES, ERBB-1; HUMANS; MALE; MUTATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SPECIMEN HANDLING;

EID: 84879924913     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31827e6984     Document Type: Article

References (25)

1. Sadowska AM, Nowe V, Janssens A, et al. Customizing systematic therapy in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol. 2011;3:207-218.
2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380-2388.
3. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212-236.
4. Querings S, Altmü ller J, Ansen S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One. 2011;6:1-8.
5. Billah S, Steward J, Staerkel G, et al. EGFR and KRAS mutations in lung carcinoma: Molecular testing by using cytology specimens. Cancer Cytopathol. 2011;119:111-117.
6. Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of EGFR mutation status in cytology specimens: An institutional experience. Diagn Cytopathol. 2011. doi: 10.1002/dc.21851.
7. Smousr JH, Cibas ES, Jänne PA, et al. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of non-small cell lung cancer. Cancer Cytopathol. 2009;117:67-72.
8. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
9. Travis WD, Brambilla E, Schil PV, et al. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur Respir J. 2011;38:239-243.
10. Hlinkova K, Babal P, Berzinec P, et al. Rapid and efficient detection of EGFR mutations in problematic cytologic specimens by Highresolution melting analysis. Mol Diagn Ther. 2011;15:21-29.
11. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International association for the study of lung cancer/American thoracic society/European respiratory society classification. Arch Pathol Lab Med. 2012;136:1-17.
12. Edwards J, Going JJ, Bartlett JMS. Microdissection and extraction of DNA from archival tissue. Methods Mol Med. 2004;97:71-75.
13. Sanz-Santos J, Serra P, Andreo F, et al. Contribution of cell blocks obtained through endobronchial ultrasound-guided transbronchial needle aspiration to the diagnosis of lung cancer. BMC Cancer. 2012;12:2-7.
14. Betz BL, Roh MH, Weigelin HC, et al. The application of molecular diagnostic studies interrogating EGFR and KRAS mutations to stained cytologic smears of lung carcinoma. Am J Clin Pathol. 2011;136:564-571.
15. Hiljsmans CJ, Damen J, Linden JC, et al. Comparative analysis of four methods to extract DNA from paraffin-embedded tissue: effect on downstream molecular applications. BMC Res Notes. 2010;3: 239-247.
16. Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6:451-458.
17. Leary AF, Gonzalez de Castro D, Nicholson AG, et al. Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors. Eur J Cancer. 2012;48:61-67.
18. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European Workshop. J Thorac Oncol. 2010;5:1706-1713.
19. Santis G, Angell R, Nickless G, et al. Screening for EGFR and KRAS mutation in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLDPCR. PLoS One. 2011;6:1-7.
20. Han HS, Lim SN, An JY, et al. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol. 2012;7:355-364.
21. Dufort S, Richard MJ, Lantuejoul S, et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res. 2011;30:57-63.
22. Chen Z, Feng J, Saldivar JS, et al. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids. Oncogene. 2008;27:4336-4343.
23. Wu SG, Chang YL, Hsu YC, et al. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist. 2008;13:1276-1284.
24. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. NatMethods. 2010;7:248-249.
25. Thunnissen E, Kerr KM, Herth FeJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small sample. Practical approach of a working group. Lung Cancer. 2012;76:1-18.